SCHEMBL19377429

SCHEMBL19377429

COc1cc(S(=O)(=O)Cc2ccc(CO)cc2)ccc1NC(=O)NC(C)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ C5 P01031 3/20 0.46
▸ POLB P06746 1/20 0.46
▸ HCRTR1 O43613 1/20 0.45
▸ HCRTR2 O43614 1/20 0.45
▸ TP53 P04637 1/20 0.45
▸ EPHX2 P34913 2/20 0.42
▸ MAPK1 P28482 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19377275 0.86 POLB (0.41) KMT2AMEN1POLBSMN1; SMN2ALDH1A1
SCHEMBL19377041 0.85 KMT2A (0.43) KMT2AMEN1C5POLBHCRTR1
SCHEMBL19377504 0.84 KMT2A (0.42) KMT2AMEN1C5POLBHCRTR1
SCHEMBL19377009 0.84 LPAR1 (0.43) KMT2AMEN1POLBSMN1; SMN2LMNA
SCHEMBL19377594 0.83 LPAR1 (0.40) KMT2AMEN1POLBALDH1A1
SCHEMBL19377598 0.82 MLNR (0.44) KMT2AMEN1C5HCRTR1HCRTR2
SCHEMBL19377527 0.81 HSD17B10 (0.58) KMT2AMEN1POLBEPHX2HSD17B10
SCHEMBL19377528 0.81 HSD17B10 (0.58) KMT2AMEN1POLBEPHX2HSD17B10
SCHEMBL19377142 0.81 KMT2A (0.40) KMT2AMEN1C5POLBHCRTR1
SCHEMBL19377512 0.81 HCRTR1 (0.43) KMT2AMEN1C5HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170275301-A1 Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof HELSINN HEALTHCARE SA (CH) 2017-09-28 — — US claimed
EP-3390355-B1 BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF HELSINN HEALTHCARE SA (CH) 2022-12-28 — — EP disclosed
US-20170275301-A1 Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof HELSINN HEALTHCARE SA (CH) 2017-09-28 — — US disclosed
US-20170275301-A1 Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof HELSINN HEALTHCARE SA (CH) 2017-09-28 — — US disclosed
US-20170275301-A1 Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof HELSINN HEALTHCARE SA (CH) 2017-09-28 — — US disclosed
WO-2017162390-A1 BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF HELSINN HEALTHCARE SA (CH) 2017-09-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170275301-A1 Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof UTS2R, GHSR, GRPR KMT2A 3175/4885MEN1 3276/4885C5 4885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback